利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.027 秒)

    Gastrin and cholecystokinin receptor ligands (III)
    2.
    发明授权
    Gastrin and cholecystokinin receptor ligands (III) 失效

    公开(公告)号：US07034048B2

    公开(公告)日：2006-04-25

    申请号：US10275613

    申请日：2001-05-04

    申请人： Sarkis Barret Kalindjian ,  Ildiko Maria Buck ,  Caroline Minli Rachel Low ,  Matthew John Tozer

    发明人： Sarkis Barret Kalindjian ,  Ildiko Maria Buck ,  Caroline Minli Rachel Low ,  Matthew John Tozer

    IPC分类号： A61K31/4164 ,  A61K31/404 ,  C07D403/04

    CPC分类号： C07D403/04 ,  A61K31/415 ,  A61K31/42 ,  A61K45/06 ,  C07D413/04 ,  A61K2300/00

    摘要： Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—(R5 being selected from H, Me, Et, Pr, Bn, OH and —CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), ═CH—, —O— or —S—; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an ═O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is —CO—NH—SO2—Ph, —SO2—NH—CO—PH, —CH2OH, or a group of the formula —R7U, (wherein U is —COOH, tetrazolyl, —CONHOH or —SO3H; and R7 is a bond; C1 to C6 hydrocarbylene optionally substituted by hydroxy, amino or acetamido; —O—(C1 to C3 alkylene)—; —SO2NR8—CHR9—; —CO—NR8—CHR9—, R8 and R9 being independently selected from H and methyl; or —NH—(CO)c—CH2, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described

    Sulfonamides and sulfamides as H.sub.3 receptor antagonists
    4.
    发明授权
    Sulfonamides and sulfamides as H.sub.3 receptor antagonists 失效
    磺酰胺和磺酰胺作为H3受体拮抗剂

    公开(公告)号：US6080871A

    公开(公告)日：2000-06-27

    申请号：US117808

    申请日：1998-10-06

    申请人： Sarkis Barret Kalindjian ,  Nigel Paul Shankley ,  Matthew John Tozer ,  Iain Mair McDonald ,  Michael John Pether ,  Elaine Anne Harper ,  Gillian Fairfull Watt ,  Tracey Cooke ,  Caroline Minli Rachel Low

    发明人： Sarkis Barret Kalindjian ,  Nigel Paul Shankley ,  Matthew John Tozer ,  Iain Mair McDonald ,  Michael John Pether ,  Elaine Anne Harper ,  Gillian Fairfull Watt ,  Tracey Cooke ,  Caroline Minli Rachel Low

    IPC分类号： A61K31/00 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/417 ,  A61P43/00 ,  C07D233/54 ,  C07D233/64 ,  C07D401/12

    CPC分类号： C07D233/64 ,  C07D401/12

    摘要： Compounds of formula (I) or (II) wherein R.sup.1 is C.sub.4 to C.sub.20 hydrocarbyl (in which one or more hydrogen atoms may be replaced by halogen, and up to three carbon atoms may be replaced by oxygen, nitrogen or sulphur atoms, provided that R.sup.1 does not contain an --O--O-- group), R.sup.2 is H or C.sub.1 to C.sub.3 alkyl, m is from 1 to 15, n is from 2 to 6, each X group is independently (a), or one X group is --N(R.sup.4)--, --O-- or --S-- and the remaining X groups are independently (a), wherein R.sup.3 is H, C.sub.1 to C.sub.6 alkyl, --CO.sub.2 R.sup.5, --CONR.sup.5.sub.2, --CR.sup.5.sub.2 OR.sup.6 or --OR.sup.5 (in which R.sup.5 and R.sup.6 are H or C.sub.1 to C.sub.3 alkyl), and R.sup.4 is H or C.sub.1 to C.sub.6 alkyl, each Y group is independently --C(R.sup.3)R.sup.4 --, or up to two Y groups are --N(R.sup.4)--, --O-- or --S-- and the remaining Y groups are independently --C(R.sup.3)R.sup.4 --, wherein R.sup.3 is as defined above, one R.sup.4 group in the structure is imidazoyl or imidazoylalkyl and the remaining R.sup.4 groups are H or C.sub.1 to C.sub.6 alkyl, and Z is >C(R.sup.7)NR.sup.2 -- or >N--, wherein R.sup.7 is any of the groups recited above for R.sup.3, and pharmaceutically acceptable salts thereof are ligands at histamine H.sub.3 receptors. ##STR1##

    摘要翻译： PCT No.PCT / GB97 / 00358 Sec。 371 1998年10月6日第 102（e）日期1998年10月6日PCT 1997年2月10日提交PCT公布。 第WO97 / 29092号公报 日期1997年8月14日其中R 1为C 4至C 20烃基（其中一个或多个氢原子可以被卤素取代，并且最多三个碳原子）可以被氧，氮或氮取代的式（I）或（II） 硫原子，条件是R1不含有-OO-基），R2为H或C1至C3烷基，m为1至15，n为2-6，X基团独立地为（a）或一个 X基团是-N（R 4） - ， - O-或-S-，其余的X基团独立地是（a），其中R 3是H，C 1 -C 6烷基，-CO 2 R 5，-CONR 52，-CR 52 OR 6或-OR 5（ 其中R5和R6是H或C1-C3烷基），R4是H或C1-C6烷基，每个Y基团独立地是-C（R3）R4-，或者最多两个Y基团是-N（R4） - ，-O-或-S-，其余的Y基团独立地为-C（R 3）R 4 - ，其中R 3如上定义，结构中的一个R 4基团为咪唑基或咪唑基烷基，其余的R 4基团为H或C 1至 C6烷基，并且Z是> C（R7）NR2-或> N-，其中R7是上述对R3所述的任何基团，并且药物 其可用的盐是组胺H3受体的配体。

    Gastrin and cholecystokinin receptor ligands(II)
    7.
    发明授权
    Gastrin and cholecystokinin receptor ligands(II) 失效

    公开(公告)号：US06878734B2

    公开(公告)日：2005-04-12

    申请号：US10275741

    申请日：2001-05-04

    申请人： Sarkis Barret Kalindjian ,  Ildiko Maria Buck ,  Katherine Isobel Mary Steel ,  Paul Trevor Wright ,  Matthew John Tozer ,  Michael John Pether ,  Caroline Minli Rachel Low

    发明人： Sarkis Barret Kalindjian ,  Ildiko Maria Buck ,  Katherine Isobel Mary Steel ,  Paul Trevor Wright ,  Matthew John Tozer ,  Michael John Pether ,  Caroline Minli Rachel Low

    IPC分类号： A61K31/42 ,  A61K45/06 ,  A61P1/04 ,  C07D233/54 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  A61K31/415 ,  C07D233/06 ,  C07D237/08 ,  C07D247/02 ,  C07D405/04 ,  C07D413/02

    CPC分类号： C07D233/64 ,  A61K31/42 ,  A61K45/06 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  A61K2300/00

    摘要： Ligands for the gastrin and cholecystokinin (CCK) receptors are provided, together with methods for preparing such ligands, and compounds which are useful intermediates in such methods. Pharmaceutical compositions comprising such ligands, methods for preparing such pharmaceutical compositions, and methods of treatment using these compositions also are provided. The ligands have the formula (I): where n is from 1 to 3; X and Y are independently ═N— or —N(R5)— where R5 is selected from the group consisting of H, Me, Et, Pr, Bn, —OH and —CH2COOR6, where R6 represents H, Me, Et, Pr or Bn; R1 is H or a C1-C15 saturated carbocylic ring optionally substituted with OMe, NMe2, CF3, Me, F, Cl, Br or I where up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 is selected from the group consisting of H, Me, Et and Pr when n is 1; or, when n is greater than 1, each R3 is independently selected from the group consisting of H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an ═O group; R4 is H or a C3 to C10 alicyclic ring where up to three H atoms may optionally be replaced by halogen atoms; Z is selected from the group consisting of: Q is a 6-membered aromatic carbocycle substituted with 1 or 2 V groups and optionally substituted with 1, 2 or 3 T groups; V is selected from the group consisting of —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, —CH2OH, or a group of the formula —R7U, where U is selected from the group consisting of —COOH, tetrazolyl, —CONHOH and —SO3H; and R7 is selected from the group consisting of a bond; C1 to C6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamido; —O—(C1 to C3 alkylene)-; —SO2NR8—CHR9—; —CO—NR8—CHR9—, where R8 and R9 are independently selected from H and methyl; and —NH—(CO)c—CH2—, where c is 0 or 1.